Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
BACKGROUND: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with ovarian cancer that had relapsed and...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826264746759815168 |
|---|---|
| author | Zweifel, M Jayson, G Reed, N Osborne, R Hassan, B Ledermann, J Shreeves, G Poupard, L Lu, S Balkissoon, J Chaplin, D Rustin, G |
| author_facet | Zweifel, M Jayson, G Reed, N Osborne, R Hassan, B Ledermann, J Shreeves, G Poupard, L Lu, S Balkissoon, J Chaplin, D Rustin, G |
| author_sort | Zweifel, M |
| collection | OXFORD |
| description | BACKGROUND: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks. RESULTS: Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited. Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia. Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine. The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%. CONCLUSIONS: The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P. A planned randomised trial will test this hypothesis. |
| first_indexed | 2024-03-06T20:12:48Z |
| format | Journal article |
| id | oxford-uuid:2b2664db-9097-4dc0-aac5-ec6b6832def6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:12:48Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:2b2664db-9097-4dc0-aac5-ec6b6832def62022-03-26T12:29:11ZPhase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:2b2664db-9097-4dc0-aac5-ec6b6832def6EnglishSymplectic Elements at Oxford2011Zweifel, MJayson, GReed, NOsborne, RHassan, BLedermann, JShreeves, GPoupard, LLu, SBalkissoon, JChaplin, DRustin, G BACKGROUND: A previous dose-escalation trial of the vascular disrupting agent combretastatin A4 phosphate (CA4P) given before carboplatin, paclitaxel, or both showed responses in 7 of 18 patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with ovarian cancer that had relapsed and who could start trial therapy within 6 months of their last platinum chemotherapy were given CA4P 63 mg/m(2) minimum 18 h before paclitaxel 175 mg/m(2) and carboplatin AUC (area under the concentration curve) 5, repeated every 3 weeks. RESULTS: Five of the first 18 patients' disease responded, so the study was extended and closed after 44 patients were recruited. Grade ≥2 toxic effects were neutropenia in 75% and thrombocytopenia in 9% of patients (weekly blood counts), tumour pain, fatigue, and neuropathy, with one patient with rapidly reversible ataxia. Hypertension (23% of patients) was controlled by glyceryl trinitrate or prophylactic amlodipine. The response rate by RECIST was 13.5% and by Gynecologic Cancer InterGroup CA 125 criteria 34%. CONCLUSIONS: The addition of CA4P to paclitaxel and carboplatin is well tolerated and appears to produce a higher response rate in this patient population than if the chemotherapy was given without CA4P. A planned randomised trial will test this hypothesis. |
| spellingShingle | Zweifel, M Jayson, G Reed, N Osborne, R Hassan, B Ledermann, J Shreeves, G Poupard, L Lu, S Balkissoon, J Chaplin, D Rustin, G Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. |
| title | Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. |
| title_full | Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. |
| title_fullStr | Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. |
| title_full_unstemmed | Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. |
| title_short | Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. |
| title_sort | phase ii trial of combretastatin a4 phosphate carboplatin and paclitaxel in patients with platinum resistant ovarian cancer |
| work_keys_str_mv | AT zweifelm phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT jaysong phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT reedn phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT osborner phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT hassanb phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT ledermannj phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT shreevesg phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT poupardl phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT lus phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT balkissoonj phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT chaplind phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer AT rusting phaseiitrialofcombretastatina4phosphatecarboplatinandpaclitaxelinpatientswithplatinumresistantovariancancer |